Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.
Escamilla-Gómez V, García Gutiérrez V, Alcalde-Mellado P, Astibia-Mahillo B, Chinea-Rodriguez A, López-Corral L, Acera-Gómez M, Torres Ochando MK, Borrero Borrego A, González Pinedo L, Zudaire Ripa T, González Vicent M, Benzaquén A, Izquierdo Garcia I, Asensi Cantó P, Montoro J, Martín-Domínguez FM, Orti G, Valcárcel D, Benitez-Carabante MI, Diaz-de-Heredia C, Cañamero E, Ferrá C, García-Cadenas I, Redondo S, Sisinni L, Perez-Martínez A, Mussetti A, Garcia-Mañó L, Palomo-Moraleda MDP, González-Sierra PA, Jurado M, Perez-Simon JA; GETH-TC. Escamilla-Gómez V, et al. Among authors: lopez corral l. Bone Marrow Transplant. 2024 Dec 11. doi: 10.1038/s41409-024-02483-0. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39663471
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
Escamilla Gómez V, García-Gutiérrez V, López Corral L, García Cadenas I, Pérez Martínez A, Márquez Malaver FJ, Caballero-Velázquez T, González Sierra PA, Viguria Alegría MC, Parra Salinas IM, Calderón Cabrera C, González Vicent M, Rodríguez Torres N, Parody Porras R, Ferra Coll C, Orti G, Valcárcel Ferreiras D, De la Cámara LLanzá R, Molés P, Velázquez-Kennedy K, João Mende M, Caballero Barrigón D, Pérez E, Martino Bofarull R, Saavedra Gerosa S, Sierra J, Poch M, Zudaire Ripa MT, Díaz Pérez MA, Molina Angulo B, Sánchez Ortega I, Sanz Caballer J, Montoro Gómez J, Espigado Tocino I, Pérez-Simón JA; Grupo Español de Trasplante Hematopoyético (GETH). Escamilla Gómez V, et al. Bone Marrow Transplant. 2020 Mar;55(3):641-648. doi: 10.1038/s41409-019-0731-x. Epub 2019 Nov 7. Bone Marrow Transplant. 2020. PMID: 31700138 Free PMC article.
Helicobacter pylori infection and graft-versus-host disease.
Velasco Guardado A, López-Corral L, Pérez-Simón JA, Caballero-Velázquez T, Flores Corral T, Caballero Barrigón D, Rodríguez Pérez A. Velasco Guardado A, et al. Biol Blood Marrow Transplant. 2011 May;17(5):765-9. doi: 10.1016/j.bbmt.2010.11.014. Epub 2010 Nov 18. Biol Blood Marrow Transplant. 2011. PMID: 21093601 Free article.
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.
Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA. Parody R, et al. Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13. Bone Marrow Transplant. 2015. PMID: 25310306 Clinical Trial.
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Kharfan-Dabaja MA, et al. Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7. Bone Marrow Transplant. 2017. PMID: 27819684 Free article.
Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.
Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D. Ortí G, et al. Bone Marrow Transplant. 2019 Jul;54(7):1133-1137. doi: 10.1038/s41409-018-0422-z. Epub 2018 Dec 13. Bone Marrow Transplant. 2019. PMID: 30546069 No abstract available.
Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation.
Ortí G, García-Cadenas I, López-Corral L, Pérez A, Jimenez MJ, Sánchez-Ortega I, Alonso L, Sisinni L, Fox L, Villacampa G, Badell I, de Heredia CD, Parody R, Ferrà C, Solano C, Caballero D, Martino R, Querol S, Valcárcel D. Ortí G, et al. Bone Marrow Transplant. 2019 Jul;54(7):1176. doi: 10.1038/s41409-019-0471-y. Bone Marrow Transplant. 2019. PMID: 30733543
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.
Caballero-Velázquez T, Calderón-Cabrera C, López-Corral L, Puig N, Marquez-Malaver F, Pérez-López E, García-Calderón C, Rosso-Fernández CM, Caballero Barrigón D, Martín J, Mateos MV, San Miguel J, Pérez-Simón JA; European Myeloma Network. Caballero-Velázquez T, et al. Bone Marrow Transplant. 2020 Feb;55(2):419-430. doi: 10.1038/s41409-019-0670-6. Epub 2019 Sep 24. Bone Marrow Transplant. 2020. PMID: 31551517 Clinical Trial.
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
Bento L, Gutiérrez A, Novelli S, Montoro J, Piñana JL, López-Corral L, Cabrero M, Martín-Sancho A, Gutiérrez-García G, Ortiz-Moscovich M, Bastos-Oreiro M, Dorado N, Pérez A, Hernani R, Ferrà C, Parody R, García-Cadenas I, Herrera P, Rodríguez G, Rodríguez N, Martín C, Yáñez L, Zanabili J, Varela MR, López-Godino O, Heras I, Español I, Martínez C, Pérez-Simón JA, Solano C, Sureda A, Sierra J, Sampol A, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfoma y Trasplante Autólogo (GELTAMO). Bento L, et al. Bone Marrow Transplant. 2021 Aug;56(8):1919-1928. doi: 10.1038/s41409-021-01264-3. Epub 2021 Mar 25. Bone Marrow Transplant. 2021. PMID: 33767400
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M, López-Corral L, Jarque I, de la Cruz-Vicente F, Pérez-López E, Valcárcel D, Sanz J, Espigado I, Ortí G, Martín-Calvo C, de la Serna J, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO). Cabrero M, et al. Bone Marrow Transplant. 2024 Mar;59(3):359-365. doi: 10.1038/s41409-023-02171-5. Epub 2024 Jan 2. Bone Marrow Transplant. 2024. PMID: 38167647 Clinical Trial.
122 results